Molecular Subtype of Small Cell Lung Cancer: Challenge for Transforming into Clinical Practice

TL;DR

This paper discusses the challenges of translating molecular subtypes of small cell lung cancer into clinical practice.

Contribution

The paper highlights recent advances in SCLC molecular subtyping and barriers to clinical application.

Findings

SCLC was traditionally considered a homogeneous disease but is now recognized as heterogeneous.

Molecular subtypes based on lineage transcription factors have been proposed.

Clinical implementation of these subtypes faces significant challenges.

Abstract

小细胞肺癌（small cell lung cancer, SCLC）是肺癌的组织学亚型之一，特点是高增殖、早转移、易耐药和复发。数年来SCLC一直被视为一种同质性疾病，治疗采用统一的放化疗策略。尽管早期疗效显著，但耐药和复发很快出现，缺乏满意的治疗效果，这可能是因为目前对SCLC的肿瘤异质性认识不足所导致。最近，临床前研究提出了基于谱系转录因子相对高表达定义的SCLC分子分型概念。本文主要阐述SCLC分子分型的现状和相关最新发现，强调分子分型转化在临床实践中所遇到的问题，旨在增进对SCLC分子分型研究进展的认识。

Figures